记者从AI制药企业英硅智能获悉,9月上旬,北京协和医院、上海市肺科医院先后完成了一例特殊的给药——全球首个由人工智能完成靶点发现与分子设计的治疗特发性肺纤维化候选药物Rentosertib,正式进入Ⅲ期临床试验首例患者给药阶段。 这不是一次普通的临床推进。它意味着,AI制药第一次真正站到了新药上市前的最后一道关卡面前。而这款药的潜力,可能不止于治疗肺纤维化。 英硅智能全自动化实验室。(受访者供图...
Source Link记者从AI制药企业英硅智能获悉,9月上旬,北京协和医院、上海市肺科医院先后完成了一例特殊的给药——全球首个由人工智能完成靶点发现与分子设计的治疗特发性肺纤维化候选药物Rentosertib,正式进入Ⅲ期临床试验首例患者给药阶段。 这不是一次普通的临床推进。它意味着,AI制药第一次真正站到了新药上市前的最后一道关卡面前。而这款药的潜力,可能不止于治疗肺纤维化。 英硅智能全自动化实验室。(受访者供图...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.